Trial
NCT02784483
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Phase ITERMINATEDREGULATORYConfidence: MEDIUM
Sponsor
Yale University
Collaborators
—
Condition
Asymptomatic Myeloma
Intervention
Atezolizumab (1200mg via IV infusion)
Why stopped
Based on FDA requirements
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-03